Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27648665 | 1.00 | CSF1R (0.33) | CSF1RCYP1A2CYP3A4CYP2C19SLC22A12 | |
| SCHEMBL14780159 | 0.86 | CSF1R (0.32) | CSF1RCYP1A2CYP3A4CYP2C19SLC22A12 | |
| SCHEMBL5751231 | 0.84 | CYP1A2 (0.34) | CSF1RCYP1A2CYP3A4CYP2C19SLC22A12 | |
| SCHEMBL27669017 | 0.82 | GPR55 (0.33) | — | |
| SCHEMBL5750833 | 0.82 | GPR55 (0.33) | — | |
| SCHEMBL22490298 | 0.76 | — | — | |
| SCHEMBL1558215 | 0.71 | CSF1R (0.41) | CSF1RSLC22A12KDM4EMEN1ALDH1A1 | |
| SCHEMBL1642687 | 0.71 | GRM5 (0.39) | CYP1A2CYP2C19MEN1ALDH1A1MAPT | |
| SCHEMBL380517 | 0.70 | TACR1 (0.37) | CYP1A2CYP3A4CYP2C19KDM4EMAPT | |
| SCHEMBL30702093 | 0.70 | TACR1 (0.37) | CYP1A2CYP3A4CYP2C19KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060199823-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | NEUROGEN CORPORATION (US) | 2006-09-07 | — | — | US | disclosed |
| EP-1680424-A2 | HETEROARYL FUSED PYRIDINES, PYRAZINES AND PYRIMIDINES AS CRF1 RECEPTOR LIGANDS | Neurogen Corporation (US) | 2006-07-19 | — | — | EP | disclosed |
| US-20050113379-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | AVENTIS PHARMACEUTICALS, INC. | 2005-05-26 | — | — | US | disclosed |
| WO-2005023806-A2 | HETEROARYL FUSED PYRIDINES, PYRAZINES AND PYRIMIDINES AS CRF1 RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199823-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | CRHR1, CRHR2, HTR5A | CSF1R 865/4885CYP1A2 3279/4885CYP3A4 3014/4885 |
| US-20050113379-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | CRHR1, CRHR2, HTR5A | CSF1R 865/4885CYP1A2 3279/4885CYP3A4 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.